Rezolute: Breakthrough in Phase 3 Study Opens Transformation to a Commercial Biotech Player - Maxim Sees 222% Price Potential for the Stock!

The release of convincing interim data from the Phase 3 clinical study "upLIFT" has brought the stock of Rezolute Inc. (RZLT) into the spotlight at the beginning of June 2026. Due to strong study results in the treatment of tumor-induced hyperinsulinism, prominent analysts are responding with massive target price increases. For investors, the research-driven company presents significant growth potential with a current market capitalization of approximately $0.3 billion, as the company is on the verge of securing a monopolistic position in the market...